Zymeworks (ZYME) EBT Margin (2021 - 2026)
Zymeworks (ZYME) posted EBT Margin of 1924.96% for Q1 2026, down 16.72% sequentially from 1649.26% in Q4 2025, and down 184329.0% YoY from N/an in Q1 2025.
Powered by 
Analysis
Zymeworks (ZYME) EBT Margin (2021 - 2026) Analysis & Trends
Zymeworks has reported EBT Margin for 6 years, with the latest figure at 1924.96% in Q1 2026.
- Quarterly EBT Margin fell 184329.0% year-over-year to 1924.96% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 127.94% (down 1317.0% YoY) and the FY2025 annual result came in at 75.26%, up 7756.0% from the prior year.
- EBT Margin fell to 1924.96% in Q1 2026 per ZYME's latest filing, from 1649.26% in the prior quarter.
- Over five years, EBT Margin peaked at 98.6% in Q4 2022 and troughed at 3794.31% in Q1 2022.
- A 5-year average of 719.14% and a median of 185.15% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2026: EBT Margin jumped 372977 bps in 2023, then sank 184329 bps in 2026.
- Over 5 years, EBT Margin stood at 98.6% in 2022, then tumbled by 215 bps to 113.46% in 2023, then surged by 49 bps to 57.33% in 2024, then sank by 2777 bps to 1649.26% in 2025, then declined by 17 bps to 1924.96% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 1924.96%, 1649.26%, and 66.15% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | -986.75% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -986.75% |
| Mar 31, 2026 | -1,924.96% |
| Dec 31, 2025 | -1,649.26% |
| Sep 30, 2025 | -66.15% |
| Jun 30, 2025 | 4.37% |
| Mar 31, 2025 | -81.67% |
| Dec 31, 2024 | -57.33% |
| Sep 30, 2024 | -185.15% |
| Jun 30, 2024 | -195.49% |
| Mar 31, 2024 | -314.84% |
| Dec 31, 2023 | -113.46% |
| Sep 30, 2023 | -167.07% |
| Jun 30, 2023 | -706.91% |
| Mar 31, 2023 | -64.54% |
| Dec 31, 2022 | 98.60% |
| Sep 30, 2022 | -1,819.65% |
| Jun 30, 2022 | -1,187.58% |
| Mar 31, 2022 | -3,794.31% |
| Dec 31, 2021 | -506.54% |
| Sep 30, 2021 | -1,360.98% |